Chronic hepatitis B virus patients had a greater chance of improving
their liver stiffness measurement value with Entecavir therapy,
according to data from a recent study.
Researchers analyzed 233 chronic hepatitis B virus (HBV) patients who underwent entecavir (ETV) therapy and received at least two liver stiffness measurements
(LSM) between August 2008 and February 2012 at Kaohsiung Chang Gung
Memorial hospital in Taiwan. The mean age of patients was 51.4 years
(168 male and 65 female). Group one consisted of 132 (56.6%) patients
and group two included 101 (43.4%) patients with cirrhosis. ETV therapy
was given to patients in a daily dose of 0.5 mg. Ten LSMs were used
from each patient.
Labels: Disease Management, entecavir, liver stiffness